Market Place
Sourcing Support
Linnaeus Therapeutics Wins Fourth SBIR Award from NCI, Total Fund
26 Mar 2025 //
PR NEWSWIRE
Linnaeus Therapeutics Publishes Paper on LNS8801 in Cancer Researh
20 Mar 2025 //
PR NEWSWIRE
Linnaeus Reports Positive LNS8801 Data In Metastatic Melanoma
16 Sep 2024 //
PR NEWSWIRE
Linnaeus Announces Issuance of Composition of Matter Patent by the EPO
02 Apr 2024 //
PR NEWSWIRE
Linnaeus Announces Presentation of Positive Clinical Data of LNS8801
06 Jun 2023 //
PR NEWSWIRE
Linnaeus Granted ODD for LNS8801 for Metastatic Cutaneous Melanoma
19 Jan 2023 //
PR NEWSWIRE
Linnaeus Therapeutics Announces Issuance of Patent for LNS8801
21 Sep 2022 //
PRNEWSWIRE
Linnaeus Announces Presentation of LNS8801 Clinical Data
12 Sep 2022 //
PRNEWSWIRE
Linnaeus Announces Presentation of Positive Data of LNS8801 at 2022 ASCO
06 Jun 2022 //
PRNEWSWIRE
Linnaeus Therapeutics to Present Pre-Clinical Data of LNS8801 at 2022 AACR
11 Apr 2022 //
PRNEWSWIRE
Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801
10 Mar 2021 //
PRNEWSWIRE
Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801
10 Mar 2021 //
PRNEWSWIRE
Linnaeus Announces Issuance of Composition of Matter Patent for LNS8801
03 Mar 2021 //
PRNEWSWIRE
Linnaeus Announces First Patient Dosed in Its Clinical Trial of LNS8801
12 Oct 2020 //
PRNEWSWIRE
Linnaeus Announces Clinical Trial Collaboration Agreement with Merck LNS8801
23 Jun 2020 //
PRNEWSWIRE
Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801
18 Jun 2020 //
PR NEWSWIRE
Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Pancreatic
10 Jun 2020 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.